Many clinical drugs for treating NAFLD have been shown to activate autophagy and affect the progression of NAFLD through different signaling pathways, including the classic hypoglycemic drug metformin (87), the well-established lipid-lowering agent simvastatin (88), and the mTOR target inhibitor rapamycin (89). This evidence concerns the gene MTOR and metabolic dysfunction-associated steatotic liver disease.